Help

Search Results

716 results

  1. CORESTA Congress, Online, 2022, Smoke Science/Product Technology Groups, ST 01

    The importance of assessing puffing topography to Inform e-cigarette emissions testing

    WADKIN R.(1); ALLEN C.(1); FEARON I.M.(2)
    (1) Broughton Life Sciences, Earby, Lancashire, U.K.; (2) whatIF? Consulting Ltd, Harwell, U.K.
    Analysis of the chemical composition of e-cigarette emissions is an important step in determining whether e-cigarettes support both individual and population-level harm reduction. Commonly, e-cigarette emissions for chemical analyses are collected by...
  2. CORESTA Congress, Online, 2022, Smoke Science/Product Technology Groups, ST 02

    Puffing topography and mouth level exposure of two closed-system Vuse e-cigarettes

    PRASAD K.; GRAY A.; EDWARD L.
    British American Tobacco, MRTP Science, Southampton, Hampshire, U.K.
    E-cigarettes have the potential to reduce the harm caused by cigarette smoking. However, product likeability and product satisfaction are important in encouraging smokers to switch to less harmful products. Actual use studies play a key part in...
  3. CORESTA Congress, Online, 2022, Smoke Science/Product Technology Groups, ST 04

    Actual use study of a heated tobacco product

    PRASAD K.(1); SHETTY M.(1); HART R.(1); EVANS E.(2); CAMPBELL C.(2); MAKENA P.(2); FEEHAN M.(4); KANITSCHEIDER C.(3); LYDEN J.(4); BAXTER S.(2)
    (1) British American Tobacco, Research and Development, Southampton, U.K.; (2) RAI Services Company, Winston-Salem, NC, U.S.A.; (3) Cerner Enviza, Munich, Germany; (4) Cerner Enviza, Kansas City, MO, U.S.A.
    The introduction of new tobacco products in the United States, including those that may be lower on the risk continuum than traditional combustible cigarettes (CC), requires premarket authorization by the FDA and information on how the products will...
  4. CORESTA Congress, Online, 2022, Smoke Science/Product Technology Groups, ST 06

    Assessing consumer use and behaviour patterns of oral nicotine pouches in a multi-country study

    PRASAD K.(1); SHETTY M.(1); KANITSCHEIDER C.(2); SZENTES B.(2); NASSAR R.(2); EDWARD L.(1)
    (1) British American Tobacco, MRTP Science, Southampton, Hampshire, U.K.; (2) Cerner Enviza RWE, Regulatory and Safety, (Diamond (KH) Germany HoldCo GmbH) Munich, Bavaria, Germany
    Due to the novel nature of oral nicotine pouches, limited studies have been conducted on the usage of these products in real-world settings. Consumption patterns and use behaviour of current nicotine pouch users need to be investigated to monitor the...
  5. CORESTA Congress, Online, 2022, Smoke Science/Product Technology Groups, ST 21

    A randomised cross-over study investigating the nicotine pharmacokinetics of nicotine pouches

    McEWAN M.; AZZOPARDI D.; GALE N.; HARDIE G.
    B.A.T. (Investments) Limited, Southampton, U.K.
    In recent years a new type of oral smokeless, tobacco-free, nicotine product has become available known as nicotine pouches (NPs). Due to their novelty, very little data are available on the nicotine pharmacokinetics (PK) of NP use. To develop a...
  7. CORESTA Congress, Online, 2022, Smoke Science/Product Technology Groups, ST 46

    Comparison of in vitro human alveolar macrophage responses after exposure to cigarette smoke and e-liquids

    HUTTER V.(1,2); HOPPER S.(3); SKAMARAUSKAS J.(2); HOFFMAN E.(1)
    (1) ImmuONE Ltd, Hatfield, Herts., U.K.; (2) Centre for Topical Drug Delivery and Toxicology, University of Hertfordshire, Hatfield, Herts., U.K.; (3) School of Clinical and Applied Sciences, Leeds Becket University, Leeds, U.K.
    Alveolar macrophages are the first line of defence against inhaled substances/particulates in the respiratory airways and determine both short- and long-term lung responses. Both cigarette smoke (CS) and e-liquid products are established to deposit...
  8. CORESTA Congress, Online, 2022, Smoke Science/Product Technology Groups, ST 47

    A 3D in vitro electronic-cigarette flavours testing strategy using cigarette smoke as context

    BISHOP E.; EAST N.; BREHENY D.; GACA M.; THORNE D.
    B.A.T. (Investments) Limited, Southampton, U.K.
    The safety of vaping and its potential as a harm reduction alternative to smoking is currently being discussed, as is the role of flavours. Here we discuss an optimised approach for the assessment of e-cigarette aerosols using 3D reconstituted airway...
  9. CORESTA Congress, Online, 2022, Smoke Science/Product Technology Groups, ST 48

    A weight of evidence review on the potential acute and chronic risks of e-cigarette use

    THORNE D.(1)*; SCOTT K.(2); GOSS C.(1); COONEY S.(1); CAMACHO O.(1); PROCTOR C.(3); MURPHY J.(1)
    (1) B.A.T. (Investments) Limited, Millbrook, Southampton, U.K.; (2) ToxDesk Ltd, Banbridge, Co. Down, U.K.; (3) DoctorProctorScience Ltd, Ascot, Berkshire, U.K.
    In order to assess the potential acute and long-term effects associated with e-cigarette use and to guide future assessments, a comprehensive review of the literature was conducted, focusing on the potential harmful effects of e-cigarette use, more...
  10. CORESTA Congress, Online, 2022, Smoke Science/Product Technology Groups, ST 49

    The use of ToxTracker for the toxicological assessment of tobacco and nicotine delivery products

    SMART D.*; BOZHILOVA S.; MIAZZI F.; HASWELL L.; GACA M.; THORNE D.; BREHENY D.
    B.A.T. (Investments) Limited, Southampton, U.K.
    The reduced risk mandate in the field of nicotine delivery has driven innovation and expansion in new technologies which requires rapid toxicological assessment to keep pace. These new products (e.g., electronic cigarettes and tobacco heating...